Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Oct 3, 2022--
The "North America Alzheimer'S Disease Therapeutics and Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
Alzheimer's disease therapeutics and diagnostics market in North America is estimated to grow with a CAGR of 6.82% over the forecast period from 2022 to 2028
The United States accounts for the leading share in the AD therapeutics and diagnostics market. Data from the National Institutes of Health (NIH) suggests that, nearly 5.8 million Americans were affected by Alzheimer's disease as of 2020. Of these, approximately 5.6 million people were in the age group of 65 years or more.
Also, according to data from the US Census Bureau, the population of Americans aged 65 or older is likely to reach 88 million individuals by 2050. As the number of elderly people in the country continues to increase, the cases of Alzheimer's will also spiral. This will enhance the demand for therapeutics and diagnostics for AD, and thus contribute to the growth of the US market.
The United States' Food and Drug Administration has approved 4 molecules, namely, galantamine, memantine, rivastigmine, and donepezil, for Alzheimer's disease treatment.
Further, as per the National Clinical Trials Registry (NCT), there are 144 Alzheimer's disease-associated clinical trials in the country currently ongoing across different phases. Such active efforts by authorities are expected to steer the market's growth.
COMPETITIVE OUTLOOK
The acclaimed players in the Alzheimer's disease therapeutics and diagnostics market are
Key Topics Covered:
1. Market Summary
2. Industry Outlook
2.1. Timeline of Alzheimer's Disease Therapeutics and Diagnostics Market
2.2. Phases and Sternness of Alzheimer's Disease
2.3. Key Insights
2.3.1. Usage of Computed Tomography for the Diagnosis of Alzheimer's Disease
2.3.2. R&D Investments in Biomarkers for Early Detection of Dementia
2.3.3. Demand for Personalized Medicines
2.4. Impact of Covid-19 on the Alzheimer's Disease Therapeutics and Diagnostics Market
2.5. Porter's Five Forces Analysis
2.6. Market Attractiveness Matrix
2.7. Vendor Scorecard
2.8. Industry Components
2.8.1. Research & Development (R & D)
2.8.2. Raw Materials
2.8.3. Manufacturing
2.8.4. Distributors/Wholesalers/Retailers
2.8.5. End-User
2.9. Key Impact Analysis
2.9.1. Effectiveness
2.9.2. Price
2.9.3. Safety
2.10. Key Market Strategies
2.10.1. Acquisitions
2.10.2. Product Launches
2.10.3. Contracts & Agreements
2.10.4. Investments & Expansions
2.11. Market Drivers
2.11.1. Prevalence of Alzheimer's Disease
2.11.2. Rise in the Elderly Population
2.12. Market Challenges
2.12.1. Failure of Late-Stage Drugs
2.12.2. Stringent Government Regulations
2.13. Market Opportunities
2.13.1. Emergence of New Diagnostic Technologies
2.13.2. Growing Number of Pipeline Drugs
3. North America Alzheimer's Disease Therapeutics and Diagnostics Market - by Therapeutics
3.1. By Drug Type
3.1.1. Marketed Drugs
3.1.2. Pipeline Drugs
3.2. By Disease Stage
3.2.1. Late Stage: Severe Ad
3.2.2. Early/Middle Stage: Mild to Moderate Ad
3.2.3. Prodromal Stage
3.3. By Generic & Branded
3.3.1. Branded
3.3.2. Generic
4. North America Alzheimer's Disease Therapeutics and Diagnostics Market - by Diagnostics
4.1. Lumbar Puncture Test
4.2. Positron Emission Tomography
4.3. Electroencephalography
4.4. Magnetic Resonance Imaging
4.5. Computed Tomography
4.6. Blood Test
4.7. Other Diagnostics
5. North America Alzheimer's Disease Therapeutics and Diagnostics Market - Country Outlook
5.1. United States
5.2. Canada
6. Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/r/wpf2ou
View source version on businesswire.com:https://www.businesswire.com/news/home/20221003005517/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 10/03/2022 06:36 AM/DISC: 10/03/2022 06:36 AM
http://www.businesswire.com/news/home/20221003005517/en